Antonio Palumbo, MD, on Multiple Myeloma: Results From the CASTOR Trial
2016 ASCO Annual MeetingAntonio Palumbo, MD, of the University of Torino, discusses this phase III study of daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (Abstract LBA4).
Related Videos
Julie R. Park, MD, on Neuroblastoma: Results of a Children’s Oncology Group Study
Julie R. Park, MD, of Seattle Children’s Hospital, discusses findings from this phase III trial of tandem myeloablative autologous stem cell transplant using peripheral blood stem cel...
Arjun Vasant Balar, MD, on Urothelial Carcinoma: Analysis of the IMvigor210 Cohort 1
Arjun Vasant Balar, MD, of the Perlmutter Cancer Center at NYU Langone Medical Center, discusses findings on atezolizumab as first-line therapy in cisplatin-ineligible locally advance...
Martin J. Van Den Bent, MD, PhD, on Anaplastic Glioma: Results from the CATNON Trial
Martin J. Van Den Bent, MD, PhD, of the Daniel den Hoed Cancer Center, discusses the interim analysis of the EORTC phase III study on concurrent and adjuvant temozolomide in anaplasti...
Rakesh Chopra, MD, and Mary Gospodarowicz, MD, on The Indian Perspective of the Current State of Cancer Research and Treatment
Rakesh Chopra, MD, of the Artemis Health Institute, and Mary Gospodarowicz, MD, of Princess Margaret Hospital, discuss oncology from an international point of view.
Charles M. Rudin, MD, PhD, on SCLC: Findings on Rovalpituzumab Tesirine
Charles M. Rudin, MD, PhD, of Memorial Sloan Kettering Cancer Center, reports on the encouraging anti-tumor activity of this antibody drug conjugate against one of the most deadly mal...
